Safety of infusing ipilimumab over 30 minutes

Journal of Clinical Oncology

Volumn 33, Issue 30, 2015, Pages 3454-3458

  Momtaz, Parisa ^a   Park, Vivian ^a   Panageas, Katherine S ^a   Postow, Michael A ^a,c   Callahan, Margaret ^a,c   Wolchok, Jedd D ^a,b,c   Chapman, Paul B ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; HYDROCORTISONE; IPILIMUMAB; PETHIDINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; ARTICLE; BACKACHE; BLOODY DIARRHEA; CHILL; CLINICAL TRIAL; COLITIS; COUGHING; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAM; FEMALE; HOT FLUSH; HUMAN; HYPOPHYSITIS; INFUSION RATE; INFUSION RELATED REACTION; MACULOPAPULAR RASH; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROPATHY; OXYGEN SATURATION; PNEUMONIA; PREMEDICATION; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; RIGOR; T WAVE INVERSION; THORAX PAIN; TREATMENT DURATION; AGED; CASE REPORT; COHORT ANALYSIS; DOSE RESPONSE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; INTRAVENOUS DRUG ADMINISTRATION; NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84945205744     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.0030     Document Type: Article

References (14)

1. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
2. Weber J, Hamid O, Amin A, et al: Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun 13:7 2013
3. Weber JS, O'Day S, Urba W, et al: Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 26:5950-5956, 2008
4. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526, 2011
5. National Cancer Institute: Common Terminology Criteria for Adverse Events v4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf
6. Chung CH: Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 13:725-732, 2008
7. Cersosimo RJ: Monoclonal antibodies in the treatment of cancer, Part 2. Am J Health Syst Pharm 60:1631-1641, 2003
8. Cersosimo RJ: Monoclonal antibodies in the treatment of cancer, Part 1. Am J Health Syst Pharm 60:1531-1548, 2003
9. Dillman RO: Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 18:465-471, 1999
10. Chung CH, Mirakhur B, Chan E, et al: Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358: 1109-1117, 2008
11. Bristol-Myers Squibb: YERVOY (ipilimumab) [US package insert]. Princeton, NJ, Bristol-Myers Squibb, 2001
12. Reidy DL, Chung KY, Timoney JP, et al: Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol 25:2691-2695, 2007
13. Pritchard CH, Greenwald MW, Kremer JM, et al: Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: Results from the RATE-RA study. BMC Musculoskelet Disord 15:177 2014
14. Ribas A, Chesney JA, Gordon MS, et al: Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med 10:236 2012